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10 Abstract
Introduction: Of the two million new HIV infections in adults in 2014, 70% occurred in sub-Saharan Africa. Several African
countries have already approved guidelines for pre-exposure prophylaxis (PrEP) for individuals at substantial risk of HIV as part of
combination HIV prevention but key questions remain about how to identify and deliver PrEP to those at greatest need.
Throughout the continent, individuals in sero-discordant relationships, and members of key populations (sex workers, men who
15 have sex with men (MSM), transgender women and injection drug users) are likely to benefit from the availability of PrEP. In
addition, adolescent girls and young women (AGYW) are at substantial risk in some parts of the continent. It has been estimated
that at least three million individuals in Africa are likely to be eligible for PrEP according to WHO’s criteria. Tens of demonstration
projects are planned or underway across the continent among a range of countries, populations and delivery settings.
Discussion: In each of the target populations, there are overarching issues related to (i) creating demand for PrEP, (ii) addressing
20 supply-side issues and (iii) providing appropriate and tailored adherence support. Critical for creating demand for PrEP is the
normalization of HIV prevention. Community-level interventions which engage opinion leaders as well as empowerment
interventions for those at highest risk will be key. Critical to supply of PrEP is that services are accessible for all, including for
stigmatized populations. Establishing accessible integrated services provides the opportunity to address other public health
priorities including the unmet need for HIV testing, contraception and sexually transmitted infections treatment. National
25 policies need to include minimum standards for training and quality assurance for PrEP implementation and to address supply
chain issues. Adherence support needs to recognize that social and structural factors are likely to have an important influence.
Combining interventions that build self-efficacy, empowerment and social cohesion, with evidence-based individualized
adherence support for PrEP, are most likely to be effective.
Conclusions: Efficacy of tenfovir-based PrEP is proven but many issues related to implementation remain unclear. Here, we have
30 summarized some of the important implementation questions that need to be assessed as PrEP is rolled out across Africa.
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Introduction
40 Of the two million new HIV infections in adults in 2014,
70% occurred in sub-Saharan Africa (SSA). With the scale-up
of antiretroviral treatment (ART), the number of new infec-
tions has stabilized [1]; however, to reach UNAIDS 90:90:90
target, it will be necessary to both scale up treatment and
45 further intensify prevention efforts [2]. Mathematical models
suggest that 25% of future HIV investments should go to
effective combination HIV prevention [3]. In 2015, WHO re-
commended the use of tenofovir-based pre-exposure pro-
phylaxis (PrEP) in individuals at substantial risk of HIV as
50 part of combination prevention [4]. This recommendation
was based on a systematic review of 18 studies across a range
of populations and settings [5]. The review found that PrEP
was effective in reducing HIV risk across gender, PrEP regimen,
dosing and mode of acquisition, and that increased adherence
55 was associated with a demonstrable increase in PrEP effec-
tiveness. There was no evidence that PrEP use was associated
with risk compensation, increased pregnancy-related outcomes
or of hormonal contraception effectiveness [5]. Among trials
with adherence ]80%, PrEP reduced risk of infection by 70%
60(RR0.30, 95% CI: 0.210.45, p0.001) [5]. Several African
countries have already licensed tenofovir plus emtricitabine for
PrEP [6], while others have started the guideline development
process, but key questions remain about how to identify and
deliver PrEP to those at greatest need.
65Maximizing the impact and cost-effectiveness of PrEP
Modelling studies suggest that the impact and cost-
effectiveness of PrEP will be greatest when used by popu-
lations at highest risk of infection, that is, those that have a
HIV incidence of about three per 100 person-years or higher
70[7]. Preliminary work by UNAIDS which aims to chart sub-
national HIV incidence across southern and eastern Africa in
men and women suggests that incidence is ]3% in at least
one age/sex group in Kenya, Lesotho, Mozambique, South
Africa, Swaziland and Uganda [8]. Throughout the continent,
75individuals in sero-discordant relationships and members
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of key populations (sex workers, men who have sex with
men (MSM), transgender women and injection drug users)
are likely to benefit from the availability of PrEP. UNAIDS
201620 has set a global target of putting 3 million people
80 on PrEP annually, focused particularly on key populations and
people at high risk in high prevalence settings [9].
While the case for making PrEP available across the con-
tinent is clear, it is important to recognize that not all those
at substantial risk of HIV acquisition will opt to start it. To
85 make an informed choice, people (and their healthcare
providers) need to be able to accurately perceive their risk
of HIV as well as their ability to mitigate it, have access to
accurate information about the effectiveness, benefits and
possible harms, and have the support and resources to be
90 able to tailor its use to their requirements and to adhere to
it. The availability of information about PrEP across Africa
has not been formally mapped but is likely suboptimal, both
among general and key populations and among healthcare
providers. How best to generate demand for PrEP to those at
95 highest risk of infection, without further stigmatizing them
(or PrEP use) is not well understood.
PrEP demonstration projects in SSA
Since completion of the efficacy trials, tens of PrEP de-
monstration projects are underway or planned across Africa
100 (see Table 1), with projects enrolling female sex workers
(FSW), MSM, adolescent girls and young women (AGYW), as
well as the general population across a range of countries. In
addition, studies are addressing the use of PrEP as bridge in
sero-discordant couples before the infected partner becomes
105 virologically suppressed on treatment and/or has acute HIV
infection [10].
PrEP provision in FSW
FSW are less engaged in HIV prevention and care services
than women in the general population [1113]. Sex work
110 is criminalized in much of Africa leading to anxiety about
confidentiality and contact with authorities [14]. FSW fre-
quently face discrimination from health providers when they do
access services [15]. Multipronged structural and community-
led interventions are required to increase access and sub-
115 sequent retention in services [1620]. PrEP implementation
projects targeting FSW have been conducted or are under-
way in Benin, Kenya [21], Senegal, South Africa and
Zimbabwe [22] (Table 1). Of note, South Africa has recently
become the first country in Africa to announce that it will
120 make antiretroviral therapy (ART)-based prevention available
for sex workers [23]. In Benin, a comprehensive prevention
package is being implemented among FSW, with PrEP and
ART being offered to 250 HIV-negative and 100 HIV-positive
FSW, respectively. Women are seen quarterly (as is the case
125 in most demonstration projects) and adherence is monitored
using self-report and pill count, as well as tenofovir blood
levels for those on PrEP, and HIV viral load (VL) monitoring
for those on ART. Given concerns that PrEP use may lead to
reductions in condom use, and increased risk of sexually
130 transmitted infections and pregnancy, the project will deter-
mine whether the use of PrEP results in decreased use of
condoms by measuring Y chromosome DNA and prostate-
specific antigen in vaginal fluid [24,25].
In Zimbabwe, PrEP is being administered as part of the
135SAPPH-IRe trial, a cluster randomized trial of a community
empowerment intervention combined with onsite access
to ART and PrEP, and supported by the ‘‘Adherence Sisters
Programme’’, which includes an adherence buddy pro-
gramme and reminder SMS combined with active follow-up
140of defaulters [26]. The primary analysis will compare the
proportion of all sex workers with a VL over 1000 copies/ml
living in intervention and comparison communities [27].
The population-level impact and cost-effectiveness will be
modelled.
145PrEP provision among MSM
Where there are data, HIV-1 incidence among MSM in Africa
is high and higher than among FSW in some settings [2830].
The pervasive homophobia that extends across Africa [31]
coupled with the widespread criminalization of sex between
150men has resulted in MSM being very poorly engaged with
prevention and care across the continent [32]. In some
African countries, there are clinics that provide tailored
services for MSM and where they exist, these are likely to be
the optimal delivery channel. In other countries, where there
155is no specific service provision, more creative solutions will
be required to engage MSM with services. There is limited
evidence that PrEP may be acceptable to MSM in Africa.
Qualitative assessments during a phase I PrEP trial of four-
month duration among MSM and FSW in Nairobi and Coastal
160Kenya in 20092010 found that while side effects were
experienced early in the study these diminished over time,
and that characteristics of pills could improve comfort and
use. Social impacts such as stigma, rumours and relationship
difficulties due to being perceived as HIV positive were
165prevalent; interventions to address HIV and ART stigma will
be important in this context [33]. Three demonstration pro-
jects are in progress among MSM in Kenya and South Africa
(see Table 1) while one more is planned and another has
been completed.
170PrEP provision among adolescents and young people
There are 10 demonstration projects either planned, com-
pleted or underway among AGYW (see Table 1) in Kenya,
South Africa, Uganda and Zimbabwe. Young women (1524)
in east and southern Africa are an important population
175for PrEP implementation. They represent three of the four
million young people living with HIV in SSA [34]. Participants
in recent HIV prevention trials, who were recruited specifi-
cally because they felt themselves at high risk of infection,
had annual HIV incidence of 59% [35,36]. Evidence from
180treatment scale up suggests that adolescents find it more
difficult to adhere to treatment than adults [37] and may
require increased adherence support, tailored to their age
group and lifestyle. One completed trial of PrEP in young
women from Cape Town demonstrated that this population
185was able to adhere to daily dosing when supported to do so
[38]. Of note, younger women in this study adhered more
reliably to daily rather than intermittent or event-driven
dosing. Several projects that are enrolling AGYW are either
underway or are in the final stages of planning, with sites in
190South Africa, Kenya, Zimbabwe and Tanzania (see Table 1).
Cowan FM et al. Journal of the International AIDS Society 2016, 19 (Suppl 6):21101
http://www.jiasociety.org/index.php/jias/article/view/21101 | http://dx.doi.org/10.7448/IAS.19.7.21101
2
Table 1. Summary of ongoing and planned PrEP demonstration projects in Africa (as of July 2016)
Project name Type of project Sites Target population Proposed enrolment Dates
Ongoing projects
Partners demonstration project Demonstration project PrEP
as a bridge to ART
Kenya, Uganda HIV sero-discordant couples 1013 HIV sero-discordant couples Ongoing since August 2013; to
complete follow-up: June 2016.
Initial results presented at CROI 2015
Choice for Adolescents Methods for
Prevention in South Africa (CHAMPS)
Demonstration project
(Pluspills, combined with
2 other projects)
South Africa Heterosexual male and female
adolescents aged 1519
150 Ongoing since July 2011; Pluspills is
expected to be completed in
October 2016; UChoose is expected
to be completed in June 2016
Sibanye Health Project: Comprehensive
HIV Prevention Package for MSM in
Southern Africa Pilot Study
Demonstration project
(pilot and integrated in
a preventive package)
South Africa MSM 200 MSM Ongoing since February 2015;
expected completion in May 2016
Sisters Antiretroviral Therapy Programme
for Prevention of HIV  An Integrated
Response (SAPPH-IRe)
Open label
(combined with TasP)
Zimbabwe FSW 1200 FSW eligible for PrEP (500
women enrolled as June 2016)
Ongoing since July 2014; expected
completion in mid-2016
Gender-Specific Combination HIV
Prevention for Youth in High Burden
Settings (MP3-Youth)
Demonstration project
(within a combination
prevention package)
Kenya Adolescent men and women
aged 1524
Only women on PrEP (enrolling
1215 total)
Ongoing since November 2014;
expected completion in November
2016
Benin Demonstration Project with CHU
de Que´bec (Canada)
Demonstration project
(combined with TasP)
Benin FSW 250 in PrEP; 100 in TasP Ongoing since October 2014;
expected completion in January
2017
Senegal Demonstration Project with
Reseau Africain De Recherche Sur Le Sida,
University of Washington and Westat
Demonstration project Senegal FSW 275 Ongoing since mid-2015; expected
completion in late-2016
TAPS Demonstration Project (Wits RHI) Demonstration project
(combined with TasP)
South Africa FSW (]18 years) 400 in PrEP; 300 in TasP Ongoing since April 2015. Expected
completion April 2017
LVCT Health and SWOP Kenya (IPCP-Kenya) Demonstration project
(within a combination
prevention package)
Kenya FSW (]18 years), MSM (]18
years), young women at high
HIV risk (1529 years)
2100 participants Ongoing; started December 2015.
Expected completion December
2016
POWER Demonstration project
(within a package including
microbicides)
South Africa, Kenya Adolescent girls and young
women aged 1624; women
aged 2529
1500 Ongoing, started July 2015, PrEP
delivery cohort to begin late 2016.
Expected completion June 2020
Anova Health Institute’s Health4Men
initiative
Demonstration project South Africa,
Lesotho, Tanzania,
Swaziland, Thailand,
Uganda
MSM 300 Ongoing; started December 2015.
Expected completion early-2016
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Table 1 (Continued )
Project name Type of project Sites Target population Proposed enrolment Dates
CAPRISA 082 Demonstration project
(observational cohort
study)
South Africa Adolescent girls and young
women aged 1824; women
aged 2530
Total enrolment of 2500, PrEP
uptake expected to
be 750
Ongoing, started March 2016.
Expected completion April 2021
Nigerian National Agency for the
Control of AIDS
Demonstration project
(combined with TasP)
Nigeria Heterosexual HIV sero-
discordant couples
Enrolling 600 individuals
on PrEP
Ongoing; started late 2015. Expected
completion in late 2017
Planned projects
EMPOWER Consortium Demonstration
Project
Demonstration project
(within a combination
package including violence
prevention)
South Africa,
Tanzania
Adolescent girls and young
women aged 1624
To be determined Planned; expected start mid-2016
Seasonal use of PrEP in Mozambique Demonstration project on
periodical use of PrEP
(feasibility phase)
Mozambique Women and men To be determined Feasibility study planning underway
DREAMS Implementation initiative Kenya, South Africa,
Uganda, Zimbabwe
Young women aged 1824 15,119; 3000; 1000; 1451 Demonstration projects starting mid-
2016
Right to care (under DREAMS) Demonstration project South Africa Adolescent girls and young
women
To be determined Planned
Tambua Mapema-PLUS Pilot study Kenya Sero-discordant couples
including patients with acute
HIV infection, identified at
care seeking
75 Planned, expected start Q4 2016
Me´decins Sans Frontie`res (MSF)
International  South Africa PrEP Project
Demonstration project South Africa Adolescent girls (B24 years
old) and MSM
To be determined Planned
HealthRight PrEP Project  Kenya Demonstration project Kenya Male sex workers (MSW) To be determined Planned
HPTN 082 Demonstration project
(observational cohort
study)
South Africa,
Zimbabwe
Young women aged 1625
years
600 Planned; start date pending ethics
submission, expected start in July
2016. Expected completion in
August 2018
UNICEF PrEP Demonstration Program Demonstration project South Africa, Brazil,
Thailand
Adolescents Total target 15,071 (South Africa
10,000; Brazil 2671; Thailand,
2400)
Planned; expected start end-2016.
Expected completion 2021
Champs PlusPills (DTHF,
University of Washington)
Demonstration project South Africa Adolescent girls and young
women aged 1625
To be determined Planned
Church of Scotland PrEP Project Demonstration project South Africa Adolescent girls who are
pregnant
To be determined Planned
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Table 1 (Continued )
Project name Type of project Sites Target population Proposed enrolment Dates
P3: Private Sector Provision of PrEP Demonstration project South Africa and
Zimbabwe
Young women aged 2034 Planned enrollment is 10,000 in
each country
Planned; expected start end-2016
IMPAACT 2009 Observational study Malawi, South
Africa, Uganda,
Zimbabwe
Adolescent girls and young
women aged 1624 who
are pregnant
To be determined Planned; expected start early-2017.
Expected completion in 2019/2020
MTN 034/IPM 045 Phase IIa open label
(randomizing participants
to either dapivirine ring or
oral PrEP)
South Africa,
Uganda, Zimbabwe
Adolescent girls and young
women aged 1617
300 Planned; expected start early-2017
Completed projects
iPrEx OLE Open-label extension South Africa,
(Brazil, Peru,
Ecuador, Thailand,
USA)
MSM and transgender women 1250 (across all sites) Completed. Open-label extension of
the iPrEx trial (Results show that
PrEP provides a high degree of
protection against HIV infection,
even for individuals who miss some
daily doses; high Interest in PrEP;
longer-term evidence of safety and
efficacy; and no sign of increased risk
behaviour among PrEP users)
Partners PrEP OLE Open-label extension Kenya, Uganda HIV sero-discordant couples 1262 (assigned to TDF or FTC/
TDF)
Completed. Open-label extension of
the partners PrEP trial; started in July
2011 and was completed in
December 2012. (Results upon OLE
completion in December 2012
showed both TDF and TDF/FTC highly
efficacious) 85% estimated efficacy
of TDF and 93% of FTC/TDF**
CDC 494 (TDF2 follow-up) Open-label extension Botswana Heterosexual men and women
aged 1839
1219 total (611 assigned to take
daily TDF/FTC pill; 608 assigned
to placebo)
Completed. Open-label extension of
the trial among heterosexual men
and women (Results presented in
July 2015 show strong adherence,
high drug levels and no HIV
infections and support efforts to
expand PrEP availability in the
context of generalized epidemics in
resource-limited settings)
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As with any medication prescribed or offered to those
under age 18, there will be questions related to who provides
consent. The only licensed drug currently available for PrEP
use is Truvada, and PrEP is currently only a licensed indication
195for those aged 18 and over. There may be reluctance among
providers to include PrEP for off-label usage. Drug safety is
also an issue; there are concerns about bone safety with
long-term use in younger populations. CHAMPS Pills Plus is
an ongoing open-label study examining the safety, feasibility
200and acceptability of daily oral Truvada as PrEP in HIV-negative
adolescents.
Although there is recognition that more intensive adher-
ence support for young people will likely be required, this
needs to be scalable. Approaches under investigation include
205individual adherence counselling, ‘‘adherence support clubs’’,
which either meet in person or virtually through ‘‘whatsapp’’
or both, use of treatment buddies, SMS and counselling on
tenfovir drug levels (HPTN 082, Pluspills). The EMPOWER
project in South Africa and Tanzania is also supporting young
210women to negotiate PrEP use within their intimate partner-
ships and within the broader social context. The DREAMS
initiative is offering PrEP to young women as part of a compre-
hensive prevention package in Kenya, South Africa, Swaziland,
Uganda and Zimbabwe with the intention of supporting pre-
215vention uptake and adherence using structural and behavioural
interventions.
PrEP provision in sero-discordant couples
There are three PrEP demonstration projects either com-
pleted or underway among sero-discordant couples (see
220Table 1) in Kenya and South Africa. Estimates of new HIV
infections occurring within stable, heterosexual partnerships
in Africa range from 30 to 60% [3944]. WHO has provided
guidance on use of PrEP for sero-discordant couples since
2013 [45,46], but the extent to which this has been incor-
225porated into national guidelines across Africa is not clear.
Identifying sero-discordant couples is critical as it allows for a
range of treatment and prevention interventions, including
those to allow safe conception [47] and to prevent transmis-
sion in pregnancy, tailored to the couple’s particular situation.
230While combining ART and PrEP for couples creates a pack-
age of mutual support and presents HIV care facilities as
favourable service delivery venues, the efficiency and accept-
ability of delivery through HIV care facilities for HIV sero-
discordant couples has not been evaluated. The Partners
235demonstration project has enrolled 1013 HIV sero-discordant
couples in Kenya and Uganda since 2013, with near elimina-
tion of HIV infection (effectiveness of 96%) [10]. Plans are
underway to recruit 1200 couples in a PrEP demonstration
project in Nigeria (see Table 1).
240PrEP provision following acute HIV-1 infection diagnosis
While PrEP may be initiated by the HIV-negative partner in
an established HIV sero-discordant partnership, identification
of discordancy for the vast majority of cases assumes de-
tection of prevalent HIV. The HIV-negative partner is at
245greatest risk of HIV-1 acquisition when the infected partner
has acute or early HIV infection [48,49]. Increasingly, there is
interest in using risk and symptom score screening algo-
rithms combined with point-of-care qualitative RNA tests [50]Ta
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to identify patients with acute HIV infection (AHI) at care
250 seeking [51]. The opportunity to identify sero-discordancy
based on AHI patients presents a new dimension for PrEP
initiation, as HIV-1 has been acquired from outside the
partnership, and the HIV-negative partner is at greatest risk
of HIV acquisition. A study among 1500 patients seeking
255 care for symptoms and screened for prevalent HIV and AHI
will start in Coastal Kenya in the second half of 2016, and
PrEP uptake among sero-discordant couples identified in the
context of care seeking will be assessed.
Discussion
260 In each of the populations discussed above, there are
overarching issues related to (i) creating demand for PrEP
for both potential users and for providers, (ii) addressing
supply-side issues and (iii) providing appropriate and tailored
adherence support [52]. It is widely agreed that PrEP will
265 need to be delivered as part of a comprehensive package of
HIV prevention services. The numerous demonstration pro-
jects now underway will evaluate different strategies for
reaching the target populations and different approaches to
implementation across populations and settings. Results of
270 these projects then need to inform locally developed and
context-specific policy recommendations which in turn facil-
itate delivery and uptake PrEP.
Demand creation
A critical first step in creating demand for PrEP is the
275 normalization of HIV prevention, without this the stigma
which undermines many HIV prevention interventions will
persist. MSM, FSW and young women are important advo-
cates for PrEP; empowering them with correct knowledge
is likely to strengthen community trust, mitigate against
280 rumours, increase acceptance, uptake and adherence. While
empowerment of key populations is critical, community-level
interventions that engage sex partners, opinion leaders and
the general population about their role in HIV prevention are
equally essential. If PrEP users come to be perceived by the
285 community as ‘‘high risk’’ or ‘‘promiscuous’’, this could greatly
undermine uptake.
Of note, there is concern among the sex work community
internationally that promoting PrEP may undermine condom
and community empowerment programmes where they
290 exist [53,54], and that rolling out PrEP to some could distract
from ensuring provision of services for all. In addition, FSW
worry that it could ‘‘re-medicalize’’ prevention, undermining
community initiatives. In some settings, there is potential for
PrEP administration to be coercive (particularly if long-acting
295 injectable preparations become available) and stigmatizing.
Implementation of PrEP in sex workers needs to be in full
collaboration with sex workers themselves and be sensitive
to the local concerns and realities that women face. Consid-
eration of the rights of sex workers (and all those eligible for
300 PrEP) is critical when formulating national implementation
plans [16].
Risk perception among young women is often poor even
among those at high risk of infection and was one of the
greatest barriers to uptake in some, but not all, of the earlier
305 PrEP trials [55]. Creating demand for PrEP among young
women will necessitate addressing barriers to prevention
uptake that young people face more generally, in addition to
providing information about the effectiveness and avail-
ability of PrEP specifically. Raising community awareness
310using messages that resonate with young women to improve
knowledge and establish norms around PrEP use and max-
imize its acceptability will be critical. Use of social media,
video and community outreach both to create demand and
inform risk assessment is planned or underway in many of the
315demonstration projects listed in Table 1.
Supply side
Critical to supply of PrEP is that services are accessible for
all, including stigmatized populations. For sero-discordant
couples, it may be possible to make PrEP available through
320existing treatment facilities, but this will not be appropriate
for the majority of potential users. For key populations, PrEP
needs to be made available through specific programmes
tailored to their requirements as well as through primary
care. Establishing accessible integrated services for young
325women and their partners will be critical to scaling-up PrEP
to this group and provides the opportunity to address other
public health priorities for young people, including the unmet
need for contraception.
Testing for HIV is the gateway to both treatment and
330biomedical prevention interventions, including for PrEP.
Although rates of testing are increasing, there are still many
people in Africa who are unaware of their status [56]. Scaling-
up testing through a range of community-based approaches
including self-testing, house-to-house and work-based ap-
335proaches, with support for linkage to services is required.
Training of health providers both to provide PrEP and trans-
form judgmental and stigmatizing behaviours is important.
In many parts of the world, misconceptions among health
providers about the effectiveness and side effects of PrEP, as
340well as the likelihood it will induce drug resistance have
slowed uptake [57]. National policies need to include mini-
mum standards for training and quality assurance for PrEP
implementation, as well as addressing supply chain issues
which secure drug availability [58].
345Making antiretroviral-based PrEP available through pre-
vention services will require a shift in how they are organized.
Antiretroviral drugs are currently procured, distributed and
monitored through treatment programmes. Services pro-
viding PrEP using outreach may require adaptation of
350pharmacy or healthcare regulations. First-generation products
will likely require a prescription from a healthcare provider,
regular re-supply and monitoring and surveillance to de-
tect ART resistance. As increasing evidence of safety emerges,
barriers to access will likely reduce (as happened with hor-
355monal contraception) [59]. There are several new products in
the pipeline [60] and services need to be positioned so that
they can introduce these as and when they are approved.
Cost is a significant consideration particularly where
there is a culture of underinvestment in prevention [3]. For
360key populations and AGYW, risk is heterogeneous both
between and within countries and finding ways to identify
and support those at highest risk will be critical. The use of
risk score tools may be appropriate but needs to be carefully
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evaluated [61,62]. Studies addressing the issues of will-
365 ingness to pay are planned in some settings globally although
the consequences of paying for PrEP when treatment is
freely available need to be considered.
Adherence support
PrEP adherence has generally been better in recent trials and
370 open-labelled studies, when the efficacy of PrEP was already
known likely changing the motivation for participation [63].
Adherence to PrEP does not need be lifelong and it is
only required to cover periods of high risk [63,64]. For MSM,
100% adherence is likely not required for prevention of
375 transmission, whereas pharmacokinetic studies among wo-
men suggest that adherence will need to be more consistent
[6567]. Some studies are exploring the use of tenofovir
levels to support adherence. While the scalability of drug
levels to monitor PrEP adherence is unlikely to be feasible
380 using existing technology, point-of-care urine assays for
tenofovir are in development. The cost of these assays will
likely range from $10 to $20 per test, which may be po-
tentially affordable for PrEP implementation programmes in
some settings [6870].
385Adherence interventions need to be responsive to the
social and structural factors that are likely to have an
important influence. Combining interventions that build self-
efficacy, empowerment and social cohesion, with evidence-
based individualized adherence support for both PrEP
390and ART, are likely to be effective and mutually reinforcing
[7174]. Interventions that work across the cascade are likely
to be more scalable and cost-effective than those that work
on only one aspect [75].
FSWs are highly mobile. Supporting continuation of access
395to PrEP (or ART) despite this mobility is likely to be critical.
Drawing on differentiated care models from the treatment
world where those stable on treatment can collect drugs less
frequently should be considered (possibly in combination
with confirmation of adherence through drug levels) [76].
400Alternatively, medication refill groups that facilitate less
frequent collection of drug by alternating collection among
group members may be an option [77].
Research monitoring and evaluation
Implementation research is underway to determine how to
405take PrEP delivery to scale across Africa in a way that is
sustainable, durable, non-stigmatizing, cost-effective and has
Table 2. Implementation research questions for different target populations
FSW MSM AGYW SD couples
Following acute
infection All
Demand
side
How to create
demand
without
stigmatizing
FSW?
How can demand be
generated safely in
countries where
MSM illegal and
highly stigmatized
How to
improve risk
perception
among AGYW?
How to assess
PrEP
readiness?
Is PrEP for
sero-discordant
couples required if
countries move to Test
and Start? If so for
how long?
Should PrEP be
considered in addition
to ART for index cases
to support safe
conception and during
pregnancy?
Is it feasible to recruit
HIV-negative partners
of individuals with
acute infection for
PrEP safely and
timeously?
What combination of
interventions most
effectively (and cost
effectively) support PrEP
How will availability of long-acting/injectable PrEP affect demand and uptake? across the prevention
Supply
side
What is the most appropriate venue for delivery of PrEP?
What level of monitoring is required to safely deliver PrEP in the ‘real world’?
What are the training and support requirements for healthcare workers delivering PrEP?
What is the minimum training standard for all healthcare workers in use of PrEP?
Are there specific supply chain issues in relation to provision of PrEP?
What is the willingness to pay for PrEP in different settings/different populations?
Does widespread use of PrEP affect population levels of ART resistance?
Are there any other perverse effects associated with widespread implementation of PrEP (risk
compensation/drug leakage from treatment programmes)?
cascade?
Adherence Can community-based models of differentiated care to support use of ART be usefully tailored to
support PrEP?
What sort of adherence support is most effective for which groups? Including mHealth, adherence clubs,
peer support?
Does use of drug levels improve adherence counselling and support?
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the greatest impact. Data are required on the relative merits
and disadvantages, including costs, of different demand
creation, delivery and adherence support models, as well as
410 real-world patterns of PrEP usage (see Table 2). Leakage of
drug from treatment programmes, particularly in the event
that PrEP is socially marketed in some settings will be
important. Determining the population-level impact will also
be important  several modelling projects are already under-
415 way to do this and will be strengthened by increasing the
availability of programme data. Ongoing research to increase
the choice of agents for PrEP needs to remain a priority [60].
Conclusions
Efficacy of tenofovir-based PrEP is proven, but many issues
420 related to implementation are still unclear. Here, we have
summarized some of the important implementation questions
that need to be assessed as PrEP is rolled out across Africa.
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